protein phosphatase 2 regulatory subunit B'epsilonGenealiases: B56E · B56epsilon
Q-omics provides the consensus-scored PPP2R5E profile across patient tissues and cancer cell-line models. PPP2R5E expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PPP2R5E is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, PPP2R5E protein abundance shows 21,812 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where PPP2R5E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP2R5E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP2R5E survival associations across molecular data types. PPP2R5E RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP2R5E RNA expression–survival associations across cancer types. High PPP2R5E expression shows unfavorable associations in ACC, KICH and LIHC, but favorable associations in KIRC, UCS and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PPP2R5E RNA expression.
This table summarizes PPP2R5E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PPP2R5E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP2R5E shows lower tumor expression in KIRC and higher tumor expression in HNSC, LIHC, LUAD, LUSC and BRCA. The HNSC box plot shows higher PPP2R5E RNA expression in tumor versus normal tissue (log2 FC = +0.799, t-test p < 0.001).
This table shows molecular features associated with PPP2R5E in patient tissues and cancer cell lines. In patient samples, PPP2R5E shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP2R5E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
